Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Long-Term Investments (2019 - 2025)

Allogene Therapeutics' Long-Term Investments history spans 7 years, with the latest figure at $24.9 million for Q3 2025.

  • For Q3 2025, Long-Term Investments changed N/A year-over-year to $24.9 million; the TTM value through Sep 2025 reached $24.9 million, changed N/A, while the annual FY2024 figure was $80.7 million, 2113.25% up from the prior year.
  • Long-Term Investments for Q3 2025 was $24.9 million at Allogene Therapeutics, down from $29.5 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $325.5 million in Q2 2021 and bottomed at $1.1 million in Q2 2024.
  • The 5-year median for Long-Term Investments is $29.9 million (2021), against an average of $50.3 million.
  • The largest annual shift saw Long-Term Investments crashed 97.84% in 2024 before it skyrocketed 2502.29% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $30.2 million in 2021, then surged by 95.87% to $59.2 million in 2022, then plummeted by 93.84% to $3.6 million in 2023, then skyrocketed by 2113.25% to $80.7 million in 2024, then plummeted by 69.08% to $24.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Long-Term Investments are $24.9 million (Q3 2025), $29.5 million (Q2 2025), and $55.5 million (Q1 2025).